|
| Thursday, 19 April 2018, 12:07 JST | |
| |  | |
Source: Eisai | |
|
|
|
TOKYO, Apr 19, 2018 - (JCN Newswire) - Eisai's subsidiary for gastrointestinal diseases EA Pharma Co., Ltd. and Mochida Pharmaceutical Co., Ltd. today announced that the bile acid transporter inhibitor "GOOFICE 5mg Tablet" (nonproprietary name: elobixibat hydrate; development code: AJG533) was listed in Japan's National Health Insurance Drug Price List as of April 18, 2018, and EA Pharma and Mochida launched the product onto Japan's market today.
GOOFICE Tablet, which EA Pharma in-licensed from Albireo AB (Sweden), is a once-daily, orally available constipation treatment with a novel action mechanism. GOOFICE Tablet inhibits the bile acid transporter that regulates reabsorption of bile acids thereby increasing the flow of bile acids to the colon. The dual action of moisture secretion and bowel movement promotion is expected to enhance natural defecation. GOOFICE Tablet is the first ileal bile acid transporter inhibitor approved anywhere in the world.
Constipation is a very common disease. The prevalence is high in young women and both elderly men and women. In Japan, the number of patients with subjective symptoms of constipation is estimated to be about 4.5 million1). In constipation, symptoms such as sensation of incomplete evacuation and hard stools appear in addition to reduction of bowel movement frequency. When such symptoms become chronic, many patients suffer a decline in QOL (quality of life). In a placebo-controlled, double-blind Phase 3 clinical study conducted in Japan, which was the basis for marketing approval, there were statistically significant improvements observed in changes in spontaneous bowel movement2) (primary endpoint), complete spontaneous bowel movement3) (secondary endpoint), time to first spontaneous bowel movement, stool consistency and other parameters for the GOOFICE Tablet-treated group compared to the placebo group. No serious adverse events were observed.
GOOFICE Tablet was jointly developed by EA Pharma and Mochida. EA Pharma and Mochida will distribute the product under the same brand name, respectively. EA Pharma and Eisai have signed a co-promotion agreement and will jointly provide information for proper use of the product.
By providing GOOFICE Tablet with its novel mechanism of action, EA Pharma, Eisai and Mochida strive to broaden treatment options for patients with chronic constipation to make a further contribution to improve patients' QOL.
1. Estimation based on the Comprehensive Survey of Living Conditions 2016 conducted by Ministry of Health, Labour and Welfare
2. Defecation without use of laxative, enema or manual disimpaction
3. Spontaneous defecation without sensation of incomplete evacuation
About EA Pharma Co., Ltd.
EA Pharma Co., Ltd., a subsidiary of Eisai Co., Ltd. for gastrointestinal disease area, was established in April 2016 by integration of the gastrointestinal business unit with at least 60 years' history of the Eisai Group and the gastrointestinal business unit of the Ajinomoto Group having amino acid as its business core. EA Pharma is a gastrointestinal specialty pharma with a full value chain covering R&D, logistics and sales & marketing.
For more information on EA Pharma Co., Ltd., please see http://www.eapharma.co.jp/.
About Mochida Pharmaceutical Co., Ltd.
Mochida Pharmaceutical Co., Ltd. has been committed to research and development of innovative pharmaceutical products since its establishment thereby providing distinctive medicines to the medical field. Currently, the core pharmaceutical business focuses resources on the targeted areas of cardiovascular, obstetrics and gynecology, dermatology, psychiatry and gastroenterology, while also providing medicine for intractable disease as well as generics including biosimilars, to meet medical needs.
For more information on Mochida Pharmaceutical Co., Ltd., please see http://www.mochida.co.jp/.
Contact:
EA Pharma Co., Ltd.
Corporate Planning Dept.
+81(0)3-6280-9802
Mochida Pharmaceutical Co., Ltd.
Public Relations
+81(0)3-3358-7211
Eisai Co., Ltd.
PR Department
+81(0)3-3817-5120
Topic: Press release summary
Source: Eisai
Sectors: Healthcare & Pharm
https://www.acnnewswire.com
From the Asia Corporate News Network
Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
|
|
|
|
|
|
|
| |
| Eisai Related News |
|
| Wednesday, 3 April 2024, 16:24 JST |
| French Sales Subsidiary Eisai S.A.S. to Divest Rights for Loxapac And Parkinane LP to CNX Therapeutics |
|
| Monday, 1 April 2024, 9:39 JST |
| Eisai Completes Submission of LEQEMBI (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease to the U.S. FDA |
|
| Friday, 29 March 2024, 15:51 JST |
| Eisai to Divest Rights for Merislon and Myonal in Japan to Kaken Pharmaceutical |
|
| Friday, 29 March 2024, 15:19 JST |
| Eisai's Brain Health Self-Check Tool "NouKNOW" is Certified as "ME-BYO BRAND" by Kanagawa Prefecture |
|
| Friday, 29 March 2024, 14:32 JST |
| Eisai: Discovery Research on Dual Orexin Receptor Antagonist Lemborexant Honored with PSJ Award for Drug Research and Development 2024 |
|
| More news >> |
|
|
|
